MA41562A1 - Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires - Google Patents

Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires

Info

Publication number
MA41562A1
MA41562A1 MA41562A MA41562A MA41562A1 MA 41562 A1 MA41562 A1 MA 41562A1 MA 41562 A MA41562 A MA 41562A MA 41562 A MA41562 A MA 41562A MA 41562 A1 MA41562 A1 MA 41562A1
Authority
MA
Morocco
Prior art keywords
agonists
heteroaryl
pyridine
hydroxy
treatment
Prior art date
Application number
MA41562A
Other languages
English (en)
Other versions
MA41562B1 (fr
Inventor
James A Johnson
Soong-Hoon Kim
R Michael Lawrence
Michael C Myers
Hannguang J Chao
Monique Phillips
Ji Jiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA41562A1 publication Critical patent/MA41562A1/fr
Publication of MA41562B1 publication Critical patent/MA41562B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule (i), dans laquelle a, x et y sont tels que définis dans la spécification, et des compositions comprenant l'un quelconque de ces nouveaux composés. Ces composés sont des agonistes d'apj qui peuvent être utilisés en tant que médicaments.
MA41562A 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires MA41562B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03
PCT/US2016/035482 WO2016196771A1 (fr) 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires

Publications (2)

Publication Number Publication Date
MA41562A1 true MA41562A1 (fr) 2018-05-31
MA41562B1 MA41562B1 (fr) 2019-05-31

Family

ID=56131647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41562A MA41562B1 (fr) 2015-06-03 2016-06-02 Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires

Country Status (35)

Country Link
US (3) US10011594B2 (fr)
EP (2) EP3303330B1 (fr)
JP (2) JP6483288B2 (fr)
KR (1) KR102066336B1 (fr)
CN (1) CN107922401B (fr)
AR (1) AR104884A1 (fr)
AU (1) AU2016270903B2 (fr)
CA (1) CA2988147C (fr)
CL (1) CL2017003055A1 (fr)
CO (1) CO2017013229A2 (fr)
CY (1) CY1121938T1 (fr)
DK (1) DK3303330T3 (fr)
EA (1) EA034912B1 (fr)
ES (1) ES2739526T3 (fr)
HK (1) HK1247915B (fr)
HR (1) HRP20191327T1 (fr)
HU (1) HUE045546T2 (fr)
IL (1) IL255951B (fr)
LT (1) LT3303330T (fr)
MA (1) MA41562B1 (fr)
ME (1) ME03474B (fr)
MX (1) MX2017014956A (fr)
MY (1) MY189453A (fr)
NZ (1) NZ738563A (fr)
PE (1) PE20180506A1 (fr)
PH (1) PH12017502158A1 (fr)
PL (1) PL3303330T3 (fr)
PT (1) PT3303330T (fr)
RS (1) RS59220B1 (fr)
SI (1) SI3303330T1 (fr)
TN (1) TN2017000503A1 (fr)
TW (1) TWI672299B (fr)
UY (1) UY36705A (fr)
WO (1) WO2016196771A1 (fr)
ZA (1) ZA201708191B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985542C (fr) 2015-05-20 2023-10-10 Amgen Inc. Triazoles agonistes du recepteur apj
SI3303330T1 (sl) 2015-06-03 2019-08-30 Bristol-Myers Squibb Company Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
BR112018007395A2 (pt) 2015-10-14 2018-10-23 Bristol-Myers Squibb Company 2,4-di-hidróxi-nicotinamidas como agonistas de apj
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
PE20181487A1 (es) * 2015-12-16 2018-09-18 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
BR112018068341A2 (pt) * 2016-03-24 2019-01-15 Bristol-Myers Squibb Company 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
EP3452466B1 (fr) 2016-05-03 2020-08-12 Amgen Inc. Composés triazole hétérocycliques utilisés en tant qu'agonistes du récepteur apj
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
JP6993357B2 (ja) 2016-06-14 2022-01-13 ブリストル－マイヤーズ スクイブ カンパニー Ａｐｊアゴニストとしての６－ヒドロキシ－５－（フェニル／ヘテロアリールスルホニル）ピリミジン－４（１ｈ）－オン
EP3526198B1 (fr) * 2016-10-14 2020-08-12 Bristol-Myers Squibb Company Agonistes d'apj de 3-sulfonyl-5-aminopyridine -2,4-diol
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093579A1 (fr) 2016-11-16 2018-05-24 Amgen Inc. Composés phényle triazole en tant qu'agonistes du récepteur apj
WO2018097944A1 (fr) 2016-11-16 2018-05-31 Amgen Inc. Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
WO2018165520A1 (fr) 2017-03-10 2018-09-13 Vps-3, Inc. Composés inhibiteurs de métalloenzymes
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
WO2024148104A1 (fr) 2023-01-03 2024-07-11 BioAge Labs, Inc. Polythérapie d'agoniste du récepteur d'apeline et d'agoniste du récepteur de glp-1 pour le traitement d'une maladie ou d'une affection associée à une prise de poids

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
MXPA03007513A (es) 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
OA12553A (en) 2001-03-28 2006-06-07 Pfizer N-Phenpropylcyclopentyl-substituted glutaramide derivatives as NEP inhibitors for FSAD.
US7399759B2 (en) 2001-09-03 2008-07-15 Takeda Pharmaceutical Company Limited 1, 3-benzothiazinone derivatives and use thereof
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
OA12771A (en) * 2002-02-14 2006-07-04 Pharmacia Corp Substituted pyridinones as modulators of P38 map kinase.
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2005004818A2 (fr) 2003-07-09 2005-01-20 Imclone Systems Incorporated Composes heterocycliques et leur utilisation comme agents anticancereux
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
JP4777974B2 (ja) 2004-04-01 2011-09-21 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体作用物質、製剤および治療的使用
CN1968922A (zh) 2004-06-18 2007-05-23 米伦纽姆医药公司 因子xa抑制剂
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
EP1655283A1 (fr) 2004-11-08 2006-05-10 Evotec OAI AG Inhibiteurs de 11béta-HSD1
EP2049497A2 (fr) * 2005-05-19 2009-04-22 Astex Therapeutics Limited Composes pharmaceutiques
WO2007023242A1 (fr) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tétrahydroquinolinones et leur usage en tant que modulateurs des récepteurs de glutamate métabotropiques
KR101332975B1 (ko) 2006-01-23 2013-11-25 암젠 인크 오로라 키나제 조절제 및 사용 방법
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
WO2008016968A2 (fr) 2006-08-03 2008-02-07 Trustees Of Tufts College Analogues de la niacine sans effets de bouffées congestives et procédés d'utilisation
WO2008019090A2 (fr) 2006-08-04 2008-02-14 Praecis Pharmaceuticals Incorporated Composés chimiques
EP1894924A1 (fr) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Composés hétérocycliques de liason du FXR
BRPI0719359A2 (pt) 2006-12-01 2014-10-07 Novartis Ag Inibidores de proteína tirosina fosfatase para a promoção de hipertrofia cardíaca fisiológica
WO2008116909A1 (fr) 2007-03-28 2008-10-02 Neurosearch A/S Dérivés de purinyle et leur utilisation en tant que modulateurs des canaux potassiques
EP2222639A1 (fr) * 2007-11-21 2010-09-01 Decode Genetics EHF Inhibiteurs de biaryle pde4 pour le traitement de troubles pulmonaires et cardiovasculaires
EP2659933A1 (fr) 2008-01-25 2013-11-06 Torrent Pharmaceuticals Ltd. Combinaisons pharmaceutiques comprenant un rupteur d'âge spécifique et autres médicaments, par exemple des médicaments anti-hypertensifs, médicaments antidiabétiques, etc.
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
RU2010154473A (ru) 2008-05-30 2012-07-10 Фостер Вилер Энергия Ой (Fi) Способ и устройство для генерации мощности сжиганием обогащенного кислородом топлива
MX2011000150A (es) 2008-06-30 2011-04-05 Cylene Pharmaceuticals Inc Compuestos de oxoindol.
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
KR20110091702A (ko) * 2008-11-04 2011-08-12 앵커 테라퓨틱스, 인코포레이티드 Ａｐｊ 수용체 화합물
BR112012006630A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)
KR20120079111A (ko) 2009-09-24 2012-07-11 에프. 호프만-라 로슈 아게 헤테로환형 항바이러스성 화합물
WO2011062955A2 (fr) 2009-11-18 2011-05-26 University Of Massachusetts Composés pour la modulation de tlr2
EP2512466A4 (fr) 2009-12-18 2013-07-03 Activesite Pharmaceuticals Inc Promédicaments d'inhibiteurs de la kallicréine plasmatique
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
US9096531B2 (en) 2010-05-24 2015-08-04 Toa Eiyo Ltd. Fused imidazole derivative
CN103237795B (zh) * 2010-09-24 2015-10-21 百时美施贵宝公司 经取代的噁二唑化合物及其作为s1p1激动剂的用途
WO2012074022A1 (fr) 2010-12-01 2012-06-07 旭硝子株式会社 Complexe cationique d'iridium et composition émettant de la lumière
EP2681205B1 (fr) 2011-03-03 2016-11-16 Universität des Saarlandes Derivés de biaryl en tant qu'inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 2
EP2697196A1 (fr) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de la kallicréine plasmatique
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
US9732051B2 (en) 2011-12-23 2017-08-15 Basf Se Isothiazoline compounds for combating invertebrate pests
EP2844655A1 (fr) * 2012-05-02 2015-03-11 Lupin Limited Composés substitués de pyridine en tant que modulateurs de crac
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
MX369290B (es) 2012-06-08 2019-11-04 Univ Of Pittsburgh Of The Commonwealth System Of Higher Education Star Inhibidores de fbx03.
US20160008339A1 (en) 2012-07-02 2016-01-14 Max-Delbruck-Centrum Fur Molekulare Medizin Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014031928A2 (fr) 2012-08-24 2014-02-27 Philip Jones Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
PL2897939T3 (pl) * 2012-09-21 2017-08-31 Sanofi Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowych
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
EP2972394A4 (fr) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer Imagerie cardiaque à ciblage hsp90 et traitement associé
WO2015017305A1 (fr) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibiteurs du canal potassique médullaire externe rénal
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
AP2016009432A0 (en) 2014-03-20 2016-09-30 Bayer Pharma AG Novel compounds
WO2015191630A1 (fr) 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Modulateurs allostériques négatifs (nam) du récepteur métabotropique du glutamate et utilisations de ceux-ci
CA2985542C (fr) 2015-05-20 2023-10-10 Amgen Inc. Triazoles agonistes du recepteur apj
SI3303330T1 (sl) 2015-06-03 2019-08-30 Bristol-Myers Squibb Company Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
BR112018007395A2 (pt) 2015-10-14 2018-10-23 Bristol-Myers Squibb Company 2,4-di-hidróxi-nicotinamidas como agonistas de apj
EP3380970B1 (fr) 2015-11-24 2023-01-04 Sanford Burnham Prebys Medical Discovery Institute Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline
PE20181269A1 (es) 2015-12-04 2018-08-03 Bristol Myers Squibb Co Agonistas del receptor de apelina y metodos de uso
EP3386976A1 (fr) 2015-12-09 2018-10-17 Research Triangle Institute, International Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations
PE20181487A1 (es) 2015-12-16 2018-09-18 Bristol Myers Squibb Co Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
BR112018068341A2 (pt) 2016-03-24 2019-01-15 Bristol-Myers Squibb Company 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
JP6993357B2 (ja) 2016-06-14 2022-01-13 ブリストル－マイヤーズ スクイブ カンパニー Ａｐｊアゴニストとしての６－ヒドロキシ－５－（フェニル／ヘテロアリールスルホニル）ピリミジン－４（１ｈ）－オン
EP3526198B1 (fr) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company Agonistes d'apj de 3-sulfonyl-5-aminopyridine -2,4-diol

Also Published As

Publication number Publication date
HUE045546T2 (hu) 2020-01-28
NZ738563A (en) 2019-09-27
MX2017014956A (es) 2018-04-13
PH12017502158A1 (en) 2018-06-11
DK3303330T3 (da) 2019-08-05
IL255951B (en) 2021-06-30
CO2017013229A2 (es) 2018-03-28
ZA201708191B (en) 2019-07-31
ES2739526T3 (es) 2020-01-31
US20190263791A1 (en) 2019-08-29
EP3530660A1 (fr) 2019-08-28
MY189453A (en) 2022-02-14
AR104884A1 (es) 2017-08-23
BR112017024846A2 (pt) 2018-08-07
CL2017003055A1 (es) 2018-05-25
AU2016270903B2 (en) 2020-04-30
TN2017000503A1 (en) 2019-04-12
JP2019094345A (ja) 2019-06-20
UY36705A (es) 2016-11-30
CN107922401A (zh) 2018-04-17
US20160355507A1 (en) 2016-12-08
CA2988147C (fr) 2023-06-13
IL255951A (en) 2018-01-31
KR20180014422A (ko) 2018-02-08
MA41562B1 (fr) 2019-05-31
WO2016196771A1 (fr) 2016-12-08
CA2988147A1 (fr) 2016-12-08
KR102066336B1 (ko) 2020-01-14
US10011594B2 (en) 2018-07-03
TWI672299B (zh) 2019-09-21
RS59220B1 (sr) 2019-10-31
LT3303330T (lt) 2019-08-12
CY1121938T1 (el) 2020-10-14
HRP20191327T1 (hr) 2019-11-01
AU2016270903A1 (en) 2018-01-18
US20180273518A1 (en) 2018-09-27
EP3303330B1 (fr) 2019-05-01
PT3303330T (pt) 2019-08-05
JP6483288B2 (ja) 2019-03-13
EA201792548A1 (ru) 2018-06-29
EP3303330A1 (fr) 2018-04-11
ME03474B (fr) 2020-01-20
PL3303330T3 (pl) 2019-10-31
JP2018516928A (ja) 2018-06-28
HK1247915B (zh) 2020-04-24
US10336739B2 (en) 2019-07-02
PE20180506A1 (es) 2018-03-09
EA034912B1 (ru) 2020-04-06
CN107922401B (zh) 2021-04-16
SI3303330T1 (sl) 2019-08-30
TW201708214A (zh) 2017-03-01

Similar Documents

Publication Publication Date Title
MA41562A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
MA39554A3 (fr) Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock
MA45020A (fr) Dérivés sulfonamides aromatiques
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA43409B1 (fr) Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
MA39374A1 (fr) Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA39927B1 (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA43913A (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2